Repertoire Immune Medicines Collaborates with Genentech to Develop T cell-Targeted Therapies for an Autoimmune Disease

Shots: Repertoire & Genentech have entered into a collaboration & license agreement to identify & develop novel T cell-targeted therapies for an autoimmune disease, leveraging Repertoire’s DECODE platform As per the deal, Genentech will handle preclinical & clinical development along with global marketing in exchange for $35M upfront & ~$730M in development, regulatory & commercial…

ByRidhi RastogiApril 24, 2025

NEWS

Genentech Reports the FDA’s sBLA Acceptance for Gazyva to Treat Lupus Nephritis

Shots: Based on positive results from P-III (REGENCY) study, the US FDA has accepted sBLA of Gazyva in Lupus Nephritis; FDA's approval decision is expected by Oct’25 The P-III (REGENCY) study demonstrated improved CRR with Gazyva + standard therapy vs standard therapy alone, along with improvements in complement levels & reductions in anti-dsDNA, markers…

ByRidhi RastogiMarch 5, 2025

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2024

Shots: The third quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Eli Lilly's acquisition of Morphic Holdings for ~$3.2B This quarter also showcased multiple clinical trial results including Roche's P-I Study Data of CT-996 to treat Obesity Our…

BySaurabh ChaubeyOctober 1, 2024

INSIGHTS+

J.P. Morgan Special: Deal Maker of the Year 2023 (Part 01)

Shots: As the year began, PharmaShots was busy analyzing the deals throughout 2023 to prepare a special report, viz. JP Morgan 2024 Special: Deal Maker of the Year 2023 (Part 01) The report features Roche, that signed 26 collaborations comprising acquisitions, contract services, development & commercialization, license, R&D, and product purchases Propelled by the invaluable…

BySenior EditorJanuary 4, 2024

INSIGHTS+

Top Performing Drug – Ocrevus (July Edition)

Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, we bring for our readers a concise yet thorough analysis of the drug Ocrevus Ocrevus is a prescription medicine used to treat adults with relapsing or primary progressive multiple sclerosis including CIS, RRMS, and SPMS PharmaShots presents…

BySenior EditorJuly 26, 2023

INSIGHTS+

Insights+: The US FDA New Drug Approvals in June 2023

Shots: The US FDA approved 12 NDAs and 3 BLA in June 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 69 novel products in 2023 In June 2023, the major highlights drugs were Talzenna + Xtandi approval for prostate cancer, Rystiggo for generalized myasthenia gravis PharmaShots…

BySenior EditorJuly 19, 2023

INSIGHTS+

Insights+: The US FDA New Drug Approvals in April 2023

Shots: The US FDA approved 6 NDAs and 4 BLA in April 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 36 novel products in 2023 In April 2023, the major highlights drugs were, Trikafta approval for children with cystic fibrosis, Qalsody for the treatment of amyotrophic…

BySenior EditorMay 17, 2023

INSIGHTS+

Insights+: The US FDA New Drug Approvals in December 2022

Shots: The US FDA approved 8 NDAs and 5 BLA in December 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 86 novel products in 2022 In December 2022, the major highlights drugs were Krazati (adagrasib) approval for non-small cell lung cancer with a KRASG12C mutation, Sunlenca…

BySenior EditorJanuary 18, 2023

INSIGHTS+

PharmaShots’ Most Read News of 2022

The year 2022 has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements, clinical trial results and gaining approvals. Our team has compiled a list of 30 most read life sciences news on PharmaShots in 2022 1. AVEO Entered into a Clinical Trial Collaboration with Merck KGaA to…

BySenior EditorJanuary 2, 2023

INSIGHTS+

Insights+ Key Biosimilars Events of September 2022

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of September, Fresenius Kabi’s Stimufend (biosimilar, pegfilgrastim) received the…

BySenior EditorOctober 6, 2022

Repertoire Immune Medicines Collaborates with Genentech to Develop T cell-Targeted Therapies for an Autoimmune Disease

Genentech Reports the FDA’s sBLA Acceptance for Gazyva to Treat Lupus Nephritis

PharmaShots’ Key Highlights of Third Quarter 2024

J.P. Morgan Special: Deal Maker of the Year 2023 (Part 01)

Top Performing Drug – Ocrevus (July Edition)

Insights+: The US FDA New Drug Approvals in June 2023

Insights+: The US FDA New Drug Approvals in April 2023

Insights+: The US FDA New Drug Approvals in December 2022

PharmaShots’ Most Read News of 2022

Insights+ Key Biosimilars Events of September 2022

Contact US

FOLLOW US